Search

Your search keyword '"Zealand Pharma A/S -- Product development -- Forecasts and trends"' showing total 3 results
Start Over Descriptor "Zealand Pharma A/S -- Product development -- Forecasts and trends"
3 results on '"Zealand Pharma A/S -- Product development -- Forecasts and trends"'

1. Post-Bariatric Hypoglycemia Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | Pasireotide Diaspartate, glucagon, Lyo avexitide

Subjects
Bayer AG -- Forecasts and trends -- Product development, Pfizer Inc. -- Product development -- Forecasts and trends, Zealand Pharma A/S -- Product development -- Forecasts and trends, Mylan N.V. -- Product development -- Forecasts and trends, Novartis AG -- Product development -- Forecasts and trends, Sun Pharmaceutical Industries Ltd. -- Forecasts and trends -- Product development, Fresenius Kabi AG -- Forecasts and trends -- Product development, Teva Pharmaceutical Industries Ltd. -- Forecasts and trends -- Product development, Business -- Research, Medical test kit industry -- Forecasts and trends -- Product development, Biological products -- Product development, Biotechnology industry -- Forecasts and trends -- Product development, Medical equipment and supplies industry -- Forecasts and trends -- Product development, Brand equity -- Forecasts and trends -- Reports, Drug approval -- Reports -- Forecasts and trends, Epidemiology -- Forecasts and trends -- Reports, Pharmaceutical industry -- Product development -- Forecasts and trends, Glucagon -- Forecasts and trends -- Reports, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-May 15, 2024-: Post-Bariatric Hypoglycemia Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | Pasireotide Diaspartate, glucagon, Lyo avexitide (C)1994-2024 M2 COMMUNICATIONS [...]

Published
2024

2. Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

Subjects
Boehringer Ingelheim GmbH -- Forecasts and trends -- Product development, Zealand Pharma A/S -- Product development -- Forecasts and trends, Obesity -- Forecasts and trends, Biotechnology industry -- Forecasts and trends -- Product development, Type 2 diabetes -- Forecasts and trends, Weight loss -- Forecasts and trends, Pharmaceutical industry -- Product development -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Phase II dose-finding trial met primary endpoint after 46 weeks [...]

Published
2023

3. Short Bowel Syndrome (SBS) Pipeline Analysis, 2022 | Insights into the FDA and EMA Approvals, Clinical Trials, Emerging Therapies | Zealand Pharma (glepaglutide), 9 Meters Biopharma (vurolenatide)

Subjects
Zealand Pharma A/S -- Product development -- Forecasts and trends, Biological products industry -- Product development -- Forecasts and trends, Business -- Research, Biotechnology industry -- Forecasts and trends -- Product development, Clinical trials -- Forecasts and trends, Malabsorption syndromes -- Forecasts and trends, Pharmaceutical industry -- Product development -- Forecasts and trends, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-October 3, 2022-: Short Bowel Syndrome (SBS) Pipeline Analysis, 2022 | Insights into the FDA and EMA Approvals, Clinical Trials, Emerging Therapies | Zealand Pharma (glepaglutide), 9 Meters Biopharma [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results